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INTRODUCTION 
Because of the high risk of hepatocellular carcinoma 
(HCC) recurrence after liver transplantation (LT), there is a 
need for strict selection criteria for performing LT in order to 
achieve an optimal prognosis. Once HCC recurs after LT, the 
outcome of the patients is quite dismal and the five-year sur-
vival rates are expected to be less than 20%.1 To avoid HCC 
recurrence after LT, careful patient selection is necessary. 
Conventionally, Milan criteria have been accepted as the gold 
standard to select LT for HCC, though several extended cri-
teria such as University of San Francisco criteria, and up-to-
seven criteria exist.2 However, we still do not have definite 
criteria to decide on LT for advanced HCC patients. Milan 
criteria would be too limited to give a chance to those pa-
tients who could get more survival benefits from LT. For this 
reason, many centers have tried to expand their selection cri-
teria.3
Despite these attempts, distant metastasis of HCC is con-
sidered to be an absolute contraindication for LT; LT cannot 
treat systemic metastasis and to date, there has been no re-
port of LT in HCC patients with distant metastasis. Herein, 
we report a pioneering case of successful LT following multi-
disciplinary down-staging treatment for a patient with ad-
vanced HCC with inferior vena cava (IVC) tumor thrombo-
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sis and lung metastasis before transplantation. This case 
report is described according to the CARE guidelines avail-
able from https://www.care-statement.org/.
CASE REPORT
A 50-year-old male was referred to our center for the treat-
ment of a large HCC in the right lobe of the liver in April 
2009. Pain in the right upper quadrant started a month be-
fore he visited a local hospital. His condition was diagnosed 
with hepatitis B virus 25 years earlier. He had been adminis-
tered lamivudine since 36 years of age; however, he quit la-
mivudine 3 years prior to the referral. He had no history of 
alcohol abuse but a smoking history of 30 pack-years. The 
patient’s general condition was good. The laboratory find-
ings were as follows: white blood cell count, 6,770/µL; hemo-
globin, 17.7 g/dL; platelets, 142,000/µL; total bilirubin, 
1.0 mg/dL; albumin, 4.1 g/dL; international normalized ra-
tio, 1.22; aspartate aminotransferase, 94 IU/L; alanine ami-
notransferase, 65 IU/L; blood urea nitrogen, 12.1 mg/dL; and 
creatinine, 0.92 mg/dL. The alpha-fetoprotein (AFP) level 
was 9.62 ng/mL, and protein induced by vitamin K absence 
Figure 2. Initial positron emission tomography computed tomography scan. A large mass with increased fluorodeoxyglucose (FDG) uptake in 
the right lobe of the liver indicated high-grade hepatocellular carcinoma. Tumor thrombosis in the inferior vena cava shows FDG uptake.
Figure 1. Initial computed tomography scan. A large hepatocellular carcinoma entirely occupied the right lobe (A), multiple satellite nodules (B) 
are seen. Tumor thrombosis is seen in the suprahepatic inferior vena cava (C) (arrows).
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or antagonist-II (PIVKA-II) level was >2,000 pg/mL. Liver 
function was preserved (Child-Pugh score, A). Serological 
tests for hepatitis B surface antigen and antibody to the core 
antigen were positive, but were negative for the antibody 
against hepatitis C virus.
Initial contrast-enhanced computed tomography (CT) 
showed a large hypervascular mass in the right lobe with he-
patic veins, IVC thrombosis, and multiple satellite nodules 
(Fig. 1). Positron emission tomography (PET)-CT showed a 
large mass with increased fluorodeoxyglucose (FDG) uptake 
in the right lobe of the liver, indicating high-grade HCC. Tu-
mor thrombosis with FDG uptake in the IVC was observed 
(Fig. 2). There was bilateral pulmonary arterial thromboem-
bolism with FDG uptake, which resulted in possible tumor 
thrombi. It revealed multifocal consolidations and ill-defined 
nodules in both lungs, which indicated infarction due to em-
bolism.
Concurrent chemoradiotherapy (CCRT) followed by he-
patic artery infusion chemotherapy (HAIC) was chosen as 
the first treatment after talks in a multidisciplinary confer-
ence.4 Three-dimensional conformal radiotherapy was per-
formed with 45 Gy in 25 fractions for 5 weeks. After CCRT, 
the primary tumor decreased and was near-totally necro-
tized. However, in the CT scan taken for response evaluation, 
there were newly developed multiple lung metastases, even 
though the primary liver tumors showed partial response to 
treatment (Fig. 3). We continued HAIC with 5-fluorouracil 
(at a dose of 500 mg/m2 for 5 hours on days 1 to 3) and cispl-
atin (at 60 mg/m2 for 2 hours on day 2). After 15 cycles of 
HAIC treatment, all hematogenous lung metastatic lesions, 
except a single lesion on the right upper lung, disappeared. 
The residual single metastatic nodule showed an increased 
size (Fig. 4A). At the multidisciplinary conference, we decid-
ed to perform lung wedge resection to remove residual nod-
ules in the lung. Video-assisted thoracoscopic (VATS) wedge 
resection was performed. The histological findings of the le-
sion showed poorly differentiated carcinoma, favoring meta-
static HCC (Fig. 4B).
Even after lung resection, HCC recurred repeatedly in oth-
er parts of the liver. We performed radiofrequency ablation 
(RFA) for a 2.6 cm-sized tumor on segment 2, 1 month after 
VATS. Transarterial chemoembolization (TACE) was per-
formed for three recurrent lesions on segment 6, 6 months 
after the RFA. Finally, another RFA treatment was applied to 
Figure 3. Liver and chest computed tomography scan after concurrent chemoradiotherapy. The primary tumor decreases and is near-totally 
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segment 2, 10 months after TACE.
After completing the above treatments for recurrent le-
sions in the liver, there were no more viable tumors in imag-
ing studies, including CT and PET-CT scans. However, liver 
function of the patient gradually worsened. His platelet count 
decreased to 22,000/µL, and his total bilirubin level was ele-
vated to 2.6 mg/dL. After extensive internal discussions on 
whether LT could be beneficial in this scenario, we decided 
to wait for more than 3 months to define the tumor charac-
teristics before progressing with LT. The patient and his fam-
ily members were very favorable toward LT and were willing 
to take the risk of HCC recurrence after LT. Meanwhile, we 
evaluated his son as a live donor. As there was no recurrence 
during the waiting period, we planned a living donor LT 
(LDLT). This LDLT procedure was accomplished 4 months 
after the last locoregional treatment, which was almost 
4 years after the initial diagnosis.
The patient underwent LDLT with a modified right lobe 
graft in January 2013. At the time of LDLT, his AFP and 
PIVKA-II tumor markers were 65.68 ng/mL in AFP and 
32 mAU/mL, respectively. He recovered uneventfully with 
standard postoperative care and immunosuppression. The 
explanted liver showed four HCCs that were near-totally 
necrotized, with no microvascular invasion (Fig. 5).
Figure 4. Chest computed tomography scan after 15 cycles of hepatic artery infusion chemotherapy. All the hematogenous lung metastatic 
lesions except a single lesion on the right upper lung disappear. The residual single metastatic nodule shows increased size (A, arrow). The 
histological findings show poorly differentiated carcinoma, favoring metastatic hepatocellular carcinoma (B, arrows indicate the tumor margin)
(hematoxylin and eosin, ×40).
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Figure 5. Explanted liver. The explanted liver shows four hepatocellular carcinoma tumors that were totally necrotized with no microvascular 
invasion. The largest tumor is 6×5.5 cm in size (on segment 5); there are no viable lesions.
185
 Dong Jin Joo, et al.
 LDLT for HCC with lung metastasis
http://e-jlc.org
We started his maintenance immunosuppression with ta-
crolimus and low-dose steroid and substituted tacrolimus 
with the mammarian target of rapamycin (mTOR) inhibitor, 
sirolimus 3 months after LT. Since then, he has been admin-
istered sirolimus monotherapy for immunosuppression 
without calcineurin inhibitors and steroids. It has been 
8 years since the patient underwent LDLT. There has been 
no HCC recurrence so far. He is doing well, without experi-
encing any complications related to LT or immunosuppres-
sion.
DISCUSSION
As HCC primarily arises from chronic liver disease, LT re-
placing the native liver has been established as the standard 
treatment in selected patients for the last two decades.5 How-
ever, applying LT to far-advanced HCC is still controversial 
because the risk of recurrence of these tumors is very high, 
and a good result may not be expected. However, many cen-
ters have attempted to expand the selection criteria for HCC 
patients in order for them to undergo LT. It seems that the 
Milan criteria would not be the Bible anymore.3,6-8 Neverthe-
less, distant metastasis of HCC is still considered an absolute 
contraindication for LT. There is no literature on successful 
LT performed on a patient with metastatic HCC. Since 2012, 
our center has been trying to expand LT criteria for advanced 
HCC through a multidisciplinary approach. When the 
down-staging for those patients succeeds, we carefully select 
them to undergo LT. We reported an acceptable result of our 
initial experience with curative LT for patients who had por-
tal vein tumor thrombosis after successful down-staging with 
CCRT.9 In this study, we reported that five patients out of 
eight had reached the 3-year mark of recurrence-free survival 
even though they were considered as a contraindication for 
LT, and their life expectancy would have been less than 
1 year without LT. From this early experience, we learned 
that careful selection could show good outcomes even for 
patients with far-advanced HCC with portal vein tumor 
thrombosis who showed good response to pretransplant lo-
coregional treatment, including CCRT. We selected one such 
patient, carefully considering the tumor biology and observ-
ing the disease progress. We discussed all possible outcomes 
with his family members, and obtained informed consent. 
All family members were eager for LT, and they were willing 
to donate their liver to the patient. Due to organ shortage 
problem, to avoid futile transplantation, strict selection crite-
ria for patients with HCC have been considered in deceased 
donor liver transplants. But, LDLT has different story be-
cause the graft should be used only for the family member. 
Thus, we could cautiously expand LT criteria for those with 
advanced HCC to include those who did not show any dis-
ease progression after down-staging therapy as long as the 
patient and family members understand all the circumstanc-
es and are willing to risk HCC recurrence in the absence of 
other options. Disease progression even after locoregional or 
systemic therapy before LT can be one of the independent 
risk factors for HCC recurrence after LT, implying aggressive 
tumor characteristics.10 Thus, we waited at least 3 months af-
ter the last RFA to perform LT and checked if there was no 
viable tumor in the liver and lung just before the transplanta-
tion. This patient had not shown any disease progression for 
over 3 months.
As HCC treatment should vary according to tumor size, 
number, location, and aggressiveness, a multidisciplinary ap-
proach is necessary to determine treatment modalities. Our 
center has regularly discussed complicated HCC cases at 
multidisciplinary conferences that include hepatologists, ra-
diation oncologists, liver surgeons, medical oncologists, in-
terventional radiologists, and nuclear medicine specialists. 
This led us to have established our unique treatment for ad-
vanced HCC, similar to the current case, which is CCRT fol-
lowed by HAIC.4 Utilizing this protocol, we have shown 
promising results, making the unresectable or non-trans-
plantable patients undergo curative surgery such as liver re-
section or transplantation.9,11 We believe the patient, in this 
case, gained the absolute benefit of multidisciplinary treat-
ment. He was a good responder to CCRT and systemic che-
motherapy, which made him undergo curative surgery.
In conclusion, we cannot generalize this case for all pa-
tients with distant metastasis of HCC. This patient might 
have been an anecdotal case. However, this report suggests 
that metastatic HCC should not be an absolute contraindica-
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tion if the patient is a good responder to combined locore-
gional and systemic therapy, and if there is no more viable 
lesion at the time of the LT procedure.
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